9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions

Key Takeaways Explain This Topic AI

Four-factor prothrombin complex concentrate (4F-PCC) combined with Vitamin K is the standard of care for the urgent reversal of warfarin in the setting of life-threatening bleeding.

Andexanet alfa is a specific reversal agent for factor Xa inhibitors (apixaban and rivaroxaban), while idarucizumab is a monoclonal antibody used to specifically reverse the direct thrombin inhibitor dabigatran.

Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition; management requires immediate cessation of all heparin products and initiation of a non-heparin anticoagulant, such as argatroban or bivalirudin.

Thrombotic Thrombocytopenic Purpura (TTP) presents with microangiopathic hemolytic anemia and thrombocytopenia; it is a medical emergency requiring urgent therapeutic plasma exchange (TPE) and avoidance of platelet transfusions.

Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-related mortality and is characterized by non-cardiogenic pulmonary edema occurring within 6 hours of a blood product transfusion.

Last updated: July 2026

Hematologic Emergencies, Anticoagulant Reversal, and Transfusions

Intensivists frequently manage life-threatening bleeding requiring rapid reversal of anticoagulation, as well as complex hematologic disorders and complications of blood product administration.

Anticoagulant Reversal

Life-threatening bleeding (e.g., intracranial hemorrhage, massive GI bleed) while on anticoagulation requires rapid, targeted reversal.

Warfarin (Vitamin K Antagonist)

Warfarin inhibits the Vitamin K Epoxide Reductase (VKOR) enzyme, depleting active Vitamin K-dependent clotting factors (II, VII, IX, X, and Proteins C and S).

Reversal Agent: 4-Factor Prothrombin Complex Concentrate (4F-PCC) + IV Vitamin K.

Mechanism: 4F-PCC (Kcentra) contains concentrated factors II, VII, IX, and X, providing immediate repletion. Vitamin K (5-10 mg IV) takes 12-24 hours to synthesize new factors and is given to sustain the reversal once the 4F-PCC wears off.

Alternative: Fresh Frozen Plasma (FFP) can be used if 4F-PCC is unavailable, but it requires large volumes (risk of volume overload/TACO), requires thawing time, and is less effective at rapidly correcting the INR.

Direct Oral Anticoagulants (DOACs)

DOACs target specific factors in the coagulation cascade.

Direct Thrombin (Factor IIa) Inhibitor: Dabigatran

Reversal: Idarucizumab (Praxbind). A monoclonal antibody fragment that binds to dabigatran with much higher affinity than dabigatran binds to thrombin.

Factor Xa Inhibitors: Apixaban, Rivaroxaban

Reversal: Andexanet alfa (Andexxa). A recombinant, inactive form of factor Xa that acts as a decoy receptor, binding the inhibitor and freeing native factor Xa.

Alternative: If Andexanet alfa is unavailable, 4F-PCC (often a fixed dose of 50 Units/kg) is frequently used off-label.

Heparins

Unfractionated Heparin (UFH) and LMWH (Enoxaparin):

Reversal: Protamine sulfate.

Dosing for UFH: 1 mg of protamine reverses approximately 100 units of UFH. Because UFH has a short half-life, only the heparin given in the last 2-2.5 hours is calculated. Max single dose is 50 mg due to risks of hypotension, bradycardia, and anaphylaxis.

Dosing for LMWH: If given within 8 hours, 1 mg protamine per 1 mg of enoxaparin. Protamine only partially (~60%) reverses the anti-Xa activity of LMWH.

Heparin-Induced Thrombocytopenia (HIT)

HIT is an immune-mediated, prothrombotic adverse drug reaction. IgG antibodies form against the heparin-Platelet Factor 4 (PF4) complex. These antibodies activate platelets, leading to thrombosis (venous > arterial) and subsequent consumptive thrombocytopenia.

Diagnosis:

4Ts Score: Evaluates Thrombocytopenia (usually a 50% drop from baseline), Timing (typically days 5-10 after heparin exposure), Thrombosis, and absence of oTher causes. A high probability score warrants immediate empiric treatment.

Laboratory Testing: PF4 ELISA (high sensitivity, low specificity) followed by a Serotonin Release Assay (SRA, high specificity, the gold standard).

Management:

Stop ALL heparin products immediately (including flushes and coated catheters).

Initiate an alternative non-heparin anticoagulant , even if no thrombosis is clinically evident, due to the high risk of new clots. Options include direct thrombin inhibitors (Argatroban, Bivalirudin) or Factor Xa inhibitors (Fondaparinux).

Note on Argatroban: Hepatically cleared; will falsely elevate the INR.

Note on Bivalirudin: Renally cleared.

Avoid Warfarin acutely, as it depletes Protein C rapidly and can cause venous limb gangrene in the setting of HIT. Warfarin is only started once platelets have fully recovered (>150,000).

Avoid Platelet Transfusions , which can add fuel to the fire (more PF4 to form complexes), unless there is life-threatening bleeding.

Thrombotic Thrombocytopenic Purpura (TTP)

TTP is a medical emergency caused by a deficiency (usually autoimmune) of ADAMTS13, a metalloprotease that cleaves large von Willebrand Factor (vWF) multimers. Uncut multimers cause widespread platelet adhesion and microthrombi in small vessels.

Clinical Pentad: Microangiopathic Hemolytic Anemia (MAHA) with schistocytes, Thrombocytopenia, Neurologic symptoms, Renal failure, and Fever. (The full pentad is rare; MAHA and thrombocytopenia alone warrant suspicion).

Management:

Therapeutic Plasma Exchange (TPE): The cornerstone of therapy. It removes the autoantibodies and replaces the missing ADAMTS13 enzyme.

Caplacizumab: An anti-vWF nanobody that blocks the interaction between vWF multimers and platelets, rapidly stopping microthrombus formation.

Immunosuppression: Corticosteroids and Rituximab to halt autoantibody production.

DO NOT transfuse platelets unless life-threatening hemorrhage is present, as this exacerbates microthrombi formation.

Massive Transfusion Protocols (MTP) and Transfusion Reactions

MTPs are utilized for severe hemorrhagic shock (e.g., trauma, GI bleed, ruptured AAA). The goal is to simulate whole blood to prevent dilutional coagulopathy.

Ratio: Most protocols use a 1:1:1 ratio of Packed Red Blood Cells (PRBCs) : Fresh Frozen Plasma (FFP) : Platelets.

Complications of MTP:

Hypocalcemia: Citrate is used as an anticoagulant in stored blood products. Massive citrate loads bind endogenous calcium, causing severe hypocalcemia, which exacerbates hypotension and coagulopathy. Calcium replacement (gluconate or chloride) is essential.

Hypothermia: Transfusing cold blood products worsens coagulopathy.

Hyperkalemia: Potassium leaks out of RBCs during storage; old blood has high potassium levels.

Transfusion Reactions

Reaction Timing/Pathophysiology Clinical Presentation Management

TRALI (Transfusion-Related Acute Lung Injury) Within 6 hrs. Donor antibodies attack recipient neutrophils in the lung. Hypoxemia, non-cardiogenic pulmonary edema (ARDS-like). Stop transfusion, supportive care (mechanical ventilation).

TACO (Transfusion-Associated Circulatory Overload) Within 6 hrs. Simple volume overload. Hypoxemia, cardiogenic pulmonary edema, elevated BNP, hypertension. Stop/slow transfusion, Diuretics, O2.

Acute Hemolytic Immediate. ABO incompatibility. Fever, flank pain, hemoglobinuria, DIC, shock. Stop transfusion immediately, aggressive IV fluids, support BP.

Febrile Non-Hemolytic Within 1-6 hrs. Cytokines in the donor product. Fever, chills. Stop transfusion, Acetaminophen.